AR-T is having a moment. Novartis (NVS) won the first Food and Drug Administration approval in August for this class of personalized cancer treatments, beating rivals in the race to sell a therapy that is custom-made with individual patients’ cells.

Manufacturing such treatments presents a challenge radically different from what most biopharma companies face in making standard drugs. Treating one patient with CAR-T — sometimes called a “living drug” — requires cells to be extracted, purified, modified to become cancer killers, and then returned to that patient.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.